Interaction of Neuromelanin with Xenobiotics and Consequences for Neurodegeneration; Promising Experimental Models
Open accessThe DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
Neuromelanin (NM) accumulates in catecholamine long-lived brain neurons that are lost in neurodegenerative diseases. NM is a complex substance made of melanic, peptide and lipid components. NM formation is a natural protective process since toxic endogenous metabolites are removed during its formation and as it binds excess metals and xenobiotics. However, disturbances of NM synthesis and function could be toxic. Here, we review recent knowledge on NM formation, toxic mechanisms involving NM, go over NM binding substances and suggest experimental models that can help identifying xenobiotic modulators of NM formation or function. Given the high likelihood of a central NM role in age-related human neurodegenerative diseases such as Parkinson’s and Alzheimer’s, resembling such diseases using animal models that do not form NM to a high degree, e.g., mice or rats, may not be optimal. Rather, use of animal models (i.e., sheep and goats) that better resemble human brain aging in terms of NM formation, as well as using human NM forming stem cellbased in vitro (e.g., mid-brain organoids) models can be more suitable. Toxicants could also be identified during chemical synthesis of NM in the test tube.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Scheme 1 The hypothesized biosynthetic pathway of NM is schematically shown to proceed through four main phases. In the initial Phase 1, the oxidation products of DA, or the oxidized DA metabolites [22], generated by catalytic oxidation mediated by Fe3+, or Cu2+, react with fibrillary seeds of aggregated peptides/proteins (blue) at the exposed side chains of Cys, His and Lys forming melanin (orange)-protein conjugates maintaining the fibrillary core as the only structural element. In Phase 2, the undegradable conjugates are engulfed by the phagophore and isolated from the cytosol through a double lipid membrane (yellow). The autophagic vacuoles fuse with lysosomes (blue circle) in Phase 3, causing interaction between the melanin-protein conjugates with other proteins, enzymes and lipids carried by lysosomes, and are transformed into autolysosomes. The resulting autolysosomes fuses with other vesicles containing lipids that attach to melanin-protein conjugates to form NM. Finally, in Phase 4 these organelles fuse with other autophagic vacuoles containing NM precursors or with mature NM organelles. A more detailed description of the entire process can be found in Zucca et al., 2018 [14].](https://figures.cochat.ai/paper-figures/b8ee9e299bc442cda619b3404ba5faf4/interaction-of-neuromelanin-with-xenobiotics-and-consequences-for-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Neuromelanin is sparse or absent in lower animals (229, 233–235), which do not contract sporadic PD (236).”
From Chemiexcitation: Mammalian Photochemistry in the Dark† (2023) · cites this paper as [236]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 2×
“To clarify these mechanisms, expression of MHC-I was induced in cultured neurons by exposure to factors commonly released by microglia activated by NM or α-synuclein, known microglia activators [36] and both present extracellularly in PD brains, or in condition of high oxidative stress derived by high cytosolic DA.”
BackgroundSelf-citationMcGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301 · cited 1×
“A typical neuropathological feature of PD is the presence of extracellular NM in the degenerating SN tissue [31], due to the conspicuous and selective death of pigmented dopaminergic neurons over the disease [32].”
BackgroundDexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149
The physical and chemical properties of eumelanin
Meredith, P., & Sarna, T. (2006) · Pigment Cell Research · doi:10.1111/j.1600-0749.2006.00345.x · Cited by 1,033
Zarow, C., Lyness, S. A., Mortimer, J. A., & Chui, H. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.337 · Cited by 1,002
Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease
Burbulla, L. F., Song, P., Mazzulli, J. R., Zampese, E., Wong, Y. C., Jeon, S., Santos, D. P., Blanz, J., Obermaier, C. D., Strojny, C., et al. (2017) · Science · doi:10.1126/science.aam9080 · Cited by 874
Jo, J., Xiao, Y., Sun, A. X., Cukuroglu, E., Tran, H.-D., Göke, J., Tan, Z. Y., Saw, T. Y., Tan, C.-P., Lokman, H., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.07.005 · Cited by 861
Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791 · cited 1×
“Notably, in SN of PD patients and those with Parkinsonian syndromes numerous activated microglia cells have been observed in close proximity of degenerating neurons and free NM debris [33,34] which were also observed inside reactive microglia [31].”
BackgroundOxidative stress in the aging substantia nigra and the etiology of Parkinson's disease
Trist, B. G., Hare, D. J., & Double, K. L. (2019) · Aging Cell · doi:10.1111/acel.13031 · Cited by 778
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain
Sofic, E., Riederer, P., Heinsen, H., Beckmann, H., Reynolds, G. P., Hebenstreit, G., & Youdim, M. B. H. (1988) · Journal of Neural Transmission · doi:10.1007/bf01244786 · Cited by 752
Keeney, P. M., Xie, J., Capaldi, R. A., & Bennett, J. P. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0984-06.2006 · Cited by 747
Diverse taxa of cyanobacteria produce β- N -methylamino- l -alanine, a neurotoxic amino acid
Cox, P. A., Banack, S. A., Murch, S. J., Rasmussen, U., Tien, G., Bidigare, R. R., Metcalf, J. S., Morrison, L. F., Codd, G. A., & Bergman, B. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501526102 · Cited by 707
Polydopamine and Eumelanin: From Structure–Property Relationships to a Unified Tailoring Strategy
d’Ischia, M., Napolitano, A., Ball, V., Chen, C.-T., & Buehler, M. J. (2014) · Accounts of Chemical Research · doi:10.1021/ar500273y · Cited by 668
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
Zucca, F. A., Segura-Aguilar, J., Ferrari, E., Muñoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., & Zecca, L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.012 · Cited by 659 · cited 7×
“The NM pigment has a protective function for neurons, at least in normal conditions, because it acts as a scavenger of toxic molecules and metal ions [7,8].”
BackgroundInfluentialSelf-citationMarquié, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24517 · Cited by 615
Selective vulnerability in neurodegenerative diseases
Fu, H., Hardy, J., & Duff, K. E. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0221-2 · Cited by 585 · cited 1×
“SN is strongly affected in PD and LC is early affected in both PD and AD [6].”
BackgroundZecca, L., Stroppolo, A., Gatti, A., Tampellini, D., Toscani, M., Gallorini, M., Giaveri, G., Arosio, P., Santambrogio, P., Fariello, R. G., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403495101 · Cited by 495
Self-citationMelanins and melanogenesis: from pigment cells to human health and technological applications
d'Ischia, M., Wakamatsu, K., Cicoira, F., Di Mauro, E., Garcia‐Borron, J. C., Commo, S., Galván, I., Ghanem, G., Kenzo, K., Meredith, P., et al. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12393 · Cited by 490
Self-citationStructures for amyloid fibrils
Makin, O. S., & Serpell, L. C. (2005) · The FEBS Journal · doi:10.1111/j.1742-4658.2005.05025.x · Cited by 461
Good, P. F., Olanow, C. W., & Perl, D. P. (1992) · Brain Research · doi:10.1016/0006-8993(92)91334-b · Cited by 427 · cited 1×
“Higher levels of aluminum were found in NM of PD patients compared to controls [96].”
Result(1999) · PubMed · Cited by 425
Theofilas, P., Ehrenberg, A. J., Dunlop, S., Di Lorenzo Alho, A. T., Nguy, A., Leite, R. E. P., Rodriguez, R. D., Mejia, M. B., Suemoto, C. K., Ferretti-Rebustini, R. E. D. L., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.2362 · Cited by 416
Sulzer, D., Bogulavsky, J., Larsen, K. E., Behr, G., Karatekin, E., Kleinman, M. H., Turro, N., Krantz, D., Edwards, R. H., Greene, L. A., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.22.11869 · Cited by 407
Self-citationZecca, L., Gallorini, M., Schünemann, V., Trautwein, A. X., Gerlach, M., Riederer, P., Vezzoni, P., & Tampellini, D. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00186.x · Cited by 401 · cited 5×
“NM appears to be the main iron compound in dopaminergic neurons of the SN, since ferritin expression is very low in these neurons [9,83].”
BackgroundInfluentialMechanism of 6-hydroxydopamine neurotoxicity
Glinka, Y., Gassen, M., & Youdim, M. B. H. (1997) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-6842-4_7 · Cited by 380
Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases
Betts, M. J., Kirilina, E., Otaduy, M. C. G., Ivanov, D., Acosta-Cabronero, J., Callaghan, M. F., Lambert, C., Cardenas-Blanco, A., Pine, K., Passamonti, L., et al. (2019) · Brain · doi:10.1093/brain/awz193 · Cited by 365
Self-citationFEDOROW, H., TRIBL, F., HALLIDAY, G., GERLACH, M., RIEDERER, P., & DOUBLE, K. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.02.001 · Cited by 350
MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration
Cebrián, C., Zucca, F. A., Mauri, P., Steinbeck, J. A., Studer, L., Scherzer, C. R., Kanter, E., Budhu, S., Mandelbaum, J., Vonsattel, J. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms4633 · Cited by 338
Self-citationWilms, H., Rosenstiel, P., Sievers, J., Deuschl, G., Zecca, L., & Lucius, R. (2003) · The FASEB Journal · doi:10.1096/fj.02-0314fje · Cited by 337
Self-citationImpaired dopamine metabolism in Parkinson’s disease pathogenesis
Masato, A., Plotegher, N., Boassa, D., & Bubacco, L. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0332-6 · Cited by 328
Kendrick, K. M., da Costa, A. P., Leigh, A. E., Hinton, M. R., & Peirce, J. W. (2001) · Nature · doi:10.1038/35102669 · Cited by 318
Dunlop, R. A., Cox, P. A., Banack, S. A., & Rodgers, K. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075376 · Cited by 314
Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis
Jellinger, K., Kienzl, E., Rumpelmair, G., Riederer, P., Stachelberger, H., Ben‐Shachar, D., & Youdim, M. B. H. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08362.x · Cited by 313 · cited 1×
“In conditions of iron overload, like those in PD [90–92], the binding sites of NM could be saturated and an increased content of redox-active iron has been found in NM of SN of PD patients [93,94].”
BackgroundSelectivity of the Parkinsonian Neurotoxin MPTP: Toxic Metabolite MPP + Binds to Neuromelanin
D'Amato, R. J., Lipman, Z. P., & Snyder, S. H. (1986) · Science · doi:10.1126/science.3080808 · Cited by 296
Zecca, L., Fariello, R., Riederer, P., Sulzer, D., Gatti, A., & Tampellini, D. (2002) · FEBS Letters · doi:10.1016/s0014-5793(01)03269-0 · Cited by 285
Self-citationMonzani, E., Nicolis, S., Dell'Acqua, S., Capucciati, A., Bacchella, C., Zucca, F. A., Mosharov, E. V., Sulzer, D., Zecca, L., & Casella, L. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201811122 · Cited by 271
Self-citationInden, M., Kitamura, Y., Takeuchi, H., Yanagida, T., Takata, K., Kobayashi, Y., Taniguchi, T., Yoshimoto, K., Kaneko, M., Okuma, Y., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04440.x · Cited by 260
Zhang, W., Phillips, K., Wielgus, A. R., Liu, J., Albertini, A., Zucca, F. A., Faust, R., Qian, S. Y., Miller, D. S., Chignell, C. F., et al. (2011) · Neurotoxicity Research · doi:10.1007/s12640-009-9140-z · Cited by 257 · cited 6×
“Cell cultures studies clearly demonstrated that the neurodegeneration induced by NM-activated microglia likely involves macrophage antigen complex-1 and phagocytic oxidase of microglia [11], even though other factors could play a key role.”
BackgroundResultInfluentialSelf-citationCox, P. A., Davis, D. A., Mash, D. C., Metcalf, J. S., & Banack, S. A. (2016) · Proceedings of the Royal Society B: Biological Sciences · doi:10.1098/rspb.2015.2397 · Cited by 256
Neuromelanin of the Human Substantia Nigra: An Update
Zucca, F. A., Basso, E., Cupaioli, F. A., Ferrari, E., Sulzer, D., Casella, L., & Zecca, L. (2014) · Neurotoxicity Research · doi:10.1007/s12640-013-9435-y · Cited by 243
Self-citationZecca, L., Bellei, C., Costi, P., Albertini, A., Monzani, E., Casella, L., Gallorini, M., Bergamaschi, L., Moscatelli, A., Turro, N. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808768105 · Cited by 240 · cited 7×
“In NM probably a pheomelanic core is contained, while eumelanin is localized on the surface, forming spherical electron-dense aggregates [3,21].”
BackgroundInfluentialLai, X., Wichers, H. J., Soler‐Lopez, M., & Dijkstra, B. W. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201704616 · Cited by 235
Zecca, L., Casella, L., Albertini, A., Bellei, C., Zucca, F. A., Engelen, M., Zadlo, A., Szewczyk, G., Zareba, M., & Sarna, T. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05541.x · Cited by 233
Self-citationFaucheux, B. A., Martin, M., Beaumont, C., Hauw, J., Agid, Y., & Hirsch, E. C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01923.x · Cited by 229
Structure–function correlations in tyrosinases
Kanteev, M., Goldfeder, M., & Fishman, A. (2015) · Protein Science · doi:10.1002/pro.2734 · Cited by 229
Critical Analysis of the Melanogenic Pathway in Insects and Higher Animals
Sugumaran, M., & Barek, H. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101753 · Cited by 228
Earle, K. M. (1968) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-196801000-00001 · Cited by 227
Superoxide Dismutase 1 in Health and Disease: How a Frontline Antioxidant Becomes Neurotoxic
Trist, B. G., Hilton, J. B., Hare, D. J., Crouch, P. J., & Double, K. L. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202000451 · Cited by 225
Chiueh, C. C., Markey, S. P., Burns, R. S., Johannessen, J. N., Pert, A., & Kopin, I. J. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90221-8 · Cited by 224
Evolving basic, pathological and clinical concepts in PD
Kalia, L. V., & Lang, A. E. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.249 · Cited by 206
Zecca, L., Wilms, H., Geick, S., Claasen, J.-H., Brandenburg, L.-O., Holzknecht, C., Panizza, M. L., Zucca, F. A., Deuschl, G., Sievers, J., et al. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0361-7 · Cited by 205
Self-citationInteraction of neuromelanin and iron in substantia nigra and other areas of human brain
Zecca, L., Shima, T., Stroppolo, A., Goj, C., Battiston, G. A., Gerbasi, R., Sarna, T., & Swartz, H. M. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00047-4 · Cited by 196
Self-citationSulzer, D., Mosharov, E., Talloczy, Z., Zucca, F. A., Simon, J. D., & Zecca, L. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05385.x · Cited by 191
Self-citationThe structure of neuromelanin as studied by chemical degradative methods
Wakamatsu, K., Fujikawa, K., Zucca, F. A., Zecca, L., & Ito, S. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01917.x · Cited by 172
Self-citationBiomedical applications of sheep models: from asthma to vaccines
Scheerlinck, J.-P. Y., Snibson, K. J., Bowles, V. M., & Sutton, P. (2008) · Trends in Biotechnology · doi:10.1016/j.tibtech.2008.02.002 · Cited by 170
Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease
Vila, M. (2019) · Movement Disorders · doi:10.1002/mds.27776 · Cited by 168
Zucca, F. A., Vanna, R., Cupaioli, F. A., Bellei, C., Palma, A. D., Silvestre, D. D., Mauri, P., Grassi, S., Prinetti, A., Casella, L., et al. (2018) · npj Parkinson s Disease · doi:10.1038/s41531-018-0050-8 · Cited by 167
Self-citationMyhre, O., Utkilen, H., Duale, N., Brunborg, G., & Hofer, T. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/726954 · Cited by 164
Self-citationIron and Other Metals in Neuromelanin, Substantia Nigra, and Putamen of Human Brain
Zecca, L., Pietra, R., Goj, C., Mecacci, C., Radice, D., & Sabbioni, E. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62031097.x · Cited by 163
Self-citationWhole-Body Lifetime Occupational Lead Exposure and Risk of Parkinson’s Disease
Coon, S., Stark, A., Peterson, E., Gloi, A., Kortsha, G., Pounds, J., Chettle, D., & Gorell, J. (2006) · Environmental Health Perspectives · doi:10.1289/ehp.9102 · Cited by 161
Animal Models for Parkinson’s Disease Research: Trends in the 2000s
Kin, K., Yasuhara, T., Kameda, M., & Date, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215402 · Cited by 161
Bush, W. D., Garguilo, J., Zucca, F. A., Albertini, A., Zecca, L., Edwards, G. S., Nemanich, R. J., & Simon, J. D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604010103 · Cited by 159
Self-citationDate, I., Felten, D. L., & Felten, S. Y. (1990) · Brain Research · doi:10.1016/0006-8993(90)90088-s · Cited by 158
Braak, H., Braak, E., & Strothjohann, M. H. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90589-4 · Cited by 157
Shima, T., Sarna, T., Swartz, H. M., Stroppolo, A., Gerbasi, R., & Zecca, L. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00623-5 · Cited by 146
Self-citationNeuromelanin and Parkinson's disease.
MARSDEN, C. D. (1983) · PubMed · Cited by 144
Zucca, F. A., Bellei, C., Giannelli, S. G., Terreni, M., Gallorini, M., Rizzio, E., Pezzoli, G., Albertini, A., & Zecca, L. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0453-2 · Cited by 138
Self-citationArzillo, M., Mangiapia, G., Pezzella, A., Heenan, R. K., Radulescu, A., Paduano, L., & d’Ischia, M. (2012) · Biomacromolecules · doi:10.1021/bm3006159 · Cited by 131 · cited 1×
“Peripheral melanins are products of the monophenolase activity of tyrosinases or catecholase activity of both tyrosinases and catechol oxidases (both copper enzymes) in animals, fungi and insects [15–17], and consist of packed eumelanic oligomers organized in π-stacked layers with typical aromatic π-interactions [18,1…”
BackgroundIn vivo imaging of neuromelanin in Parkinson’s disease using18F-AV-1451 PET
Hansen, A. K., Knudsen, K., Lillethorup, T. P., Landau, A. M., Parbo, P., Fedorova, T., Audrain, H., Bender, D., Østergaard, K., Brooks, D. J., et al. (2016) · Brain · doi:10.1093/brain/aww098 · Cited by 128
Evidence for neuromelanin involvement in MPTP-induced neurotoxicity
D’Amato, R. J., Alexander, G. M., Schwartzman, R. J., Kitt, C. A., Price, D. L., & Snyder, S. H. (1987) · Nature · doi:10.1038/327324a0 · Cited by 127
Engineering of Midbrain Organoids Containing Long-Lived Dopaminergic Neurons
Tieng, V., Stoppini, L., Villy, S., Fathi, M., Dubois‐Dauphin, M., & Krause, K. (2014) · Stem Cells and Development · doi:10.1089/scd.2013.0442 · Cited by 123
Kwak, T. H., Kang, J. H., Hali, S., Kim, J., Kim, K.-P., Park, C., Lee, J., Ryu, H. K., Na, J. E., Jo, J., et al. (2020) · Stem Cells · doi:10.1002/stem.3163 · Cited by 119
Bohic, S., Murphy, K., Paulus, W., Cloetens, P., Salome-Pateyron, M., Susini, J., & Double, K. L. (2008) · Analytical Chemistry · doi:10.1021/ac801817k · Cited by 117
Autoradiography of [14C]paraquat or [14C]diquat in frogs and mice: Accumulation in neuromelanin
Lindquist, N. G., Larsson, B. S., & Lydén‐Sokolowski, A. (1988) · Neuroscience Letters · doi:10.1016/0304-3940(88)90002-x · Cited by 115
Pigmentation in the nucleus substantiae nigrae of mammals.
MARSDEN, C. D. (1961) · PubMed Central · Cited by 114
Potential bioactivated neurotoxicants, N-methylated β-carbolinium ions, are present in human brain
Matsubara, K., Collins, M. A., Akane, A., Ikebuchi, J., Neafsey, E. J., Kagawa, M., & Shiono, H. (1993) · Brain Research · doi:10.1016/0006-8993(93)91221-d · Cited by 112
Interaction of Human Substantia Nigra Neuromelanin with Lipids and Peptides
Zecca, L., Costi, P., Mecacci, C., Ito, S., Terreni, M., & Sonnino, S. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741758.x · Cited by 109
Self-citationBoyce, S., Kelly, E., Reavill, C. A., Jenner, P. G., & MARSDEN, C. D. (1984) · Biochemical Pharmacology · doi:10.1016/0006-2952(84)90344-7 · Cited by 108
Glover, W. B., Mash, D. C., & Murch, S. J. (2014) · Amino Acids · doi:10.1007/s00726-014-1812-1 · Cited by 108
The neurotoxicity of iron, copper and cobalt in Parkinson’s disease through ROS-mediated mechanisms
Lan, A. P., Chen, J., Chai, Z., & Hu, Y. (2016) · BioMetals · doi:10.1007/s10534-016-9942-4 · Cited by 99
Huang, L. Z., Parameswaran, N., Bordia, T., McIntosh, J. M., & Quik, M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06011.x · Cited by 98
Chronic and progressive Parkinson's disease MPTP model in adult and aged mice
Muñoz‐Manchado, A. B., Villadiego, J., Romo‐Madero, S., Suárez‐Luna, N., Bermejo‐Navas, A., Rodríguez‐Gómez, J. A., Garrido‐Gil, P., Labandeira-García, J. L., Echevarría, M., López‐Barneo, J., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13409 · Cited by 97
MPTP-Induced Parkinsonism in Minipigs
Mikkelsen, M. E., Møller, A., Jensen, L. H., Pedersen, A., Harajehi, J. B., & Pakkenberg, H. (1999) · Neurotoxicology and Teratology · doi:10.1016/s0892-0362(98)00037-3 · Cited by 96
Sheep recognize familiar and unfamiliar human faces from two-dimensional images
Knolle, F., Goncalves, R. P., & Morton, A. J. (2017) · Royal Society Open Science · doi:10.1098/rsos.171228 · Cited by 96
Karlsson, O., Berg, C., Brittebo, E. B., & Lindquist, N. G. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00508.x · Cited by 87
Neurofibrillary tangles in the cerebral cortex of sheep
Nelson, P. T., Greenberg, S. G., & Saper, C. B. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90270-4 · Cited by 84
Melanin and neuromelanin binding of drugs and chemicals: toxicological implications
Karlsson, O., & Lindquist, N. G. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1757-0 · Cited by 81
Engelen, M., Vanna, R., Bellei, C., Zucca, F. A., Wakamatsu, K., Monzani, E., Ito, S., Casella, L., & Zecca, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048490 · Cited by 79
Self-citationDelcourt, N., Claudepierre, T., Maignien, T., Arnich, N., & Mattei, C. (2017) · Toxins · doi:10.3390/toxins10010006 · Cited by 73
EPR investigations of the iron domain in neuromelanin
Aime, S., Bergamasco, B., Biglino, D., Digilio, G., Fasano, M., Giamello, E., & Lopiano, L. (1997) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(97)00014-8 · Cited by 72
Synthesis and Neurotoxicity of Tetrahydroisoquinoline Derivatives for Studying Parkinson's Disease
Abe, K., Saitoh, T., Horiguchi, Y., Utsunomiya, I., & Taguchi, K. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.1355 · Cited by 72
Biesemeier, A., Eibl, O., Eswara, S., Audinot, J., Wirtz, T., Pezzoli, G., Zucca, F. A., Zecca, L., & Schraermeyer, U. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13648 · Cited by 70
Self-citationCerebral uptake and protein incorporation of cyanobacterial toxin β-N-methylamino-L-alanine
Xie, X., Basile, M. J., & Mash, D. C. (2013) · Neuroreport · doi:10.1097/wnr.0b013e328363fd89 · Cited by 69
Bjørklund, G., Hofer, T., Nurchi, V. M., & Aaseth, J. (2019) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2019.110717 · Cited by 66
Self-citationNeafsey, E. J., ALBORES, R., Gearhart, D. A., Kindel, G. H., Raikoff, K., Tamayo, F., & Collins, M. A. (1995) · Brain Research · doi:10.1016/0006-8993(95)00082-2 · Cited by 52
D’Amato, R. J., Benham, D. F., & Snyder, S. H. (1987) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1987.tb04142.x · Cited by 50
Long-term retention of neurotoxic ?-carbolines in brain neuromelanin
stergren, A. X. D., Annas, A., Skog, K. I., Lindquist, N. G., & Brittebo, E. B. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-003-0080-0 · Cited by 49
Ferrari, E., Capucciati, A., Prada, I., Zucca, F. A., D’Arrigo, G., Pontiroli, D., Bridelli, M. G., Sturini, M., Bubacco, L., Monzani, E., et al. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00231 · Cited by 49
Self-citationTribl, F., Arzberger, T., Riederer, P. F., & Gerlach, M. (2007) · Springer eBooks · doi:10.1007/978-3-211-73574-9_8 · Cited by 48
Neuromelanic pigment in substantia nigra neurons of rats and dogs
DeMattei, M., Levi, A. C., & Fariello, R. G. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90614-2 · Cited by 48
Early life exposure to permethrin: a progressive animal model of Parkinson's disease
Nasuti, C., Brunori, G., Eusepi, P., Marinelli, L., Ciccocioppo, R., & Gabbianelli, R. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.10.003 · Cited by 48
Kropf, A. J., Bunker, B. A., Eisner, M., Moss, S. C., Zecca, L., Stroppolo, A., & Crippa, P. R. (1998) · Biophysical Journal · doi:10.1016/s0006-3495(98)77755-0 · Cited by 46
Self-citationAlzheimer's disease markers in the aged sheep (Ovis aries)
Reid, S. J., Mckean, N. E., Henty, K., Portelius, E., Blennow, K., Rudiger, S. R., Bawden, C. S., Handley, R. R., Verma, P. J., Faull, R. L. M., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.020 · Cited by 46
The substantia nigra pars compacta of the Göttingen minipig: an anatomical and stereological study
Nielsen, M. S., Sørensen, J. C. H., & Bjarkam, C. R. (2009) · Brain Structure and Function · doi:10.1007/s00429-009-0217-5 · Cited by 44
Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson’s disease
Herrera, A., Muñoz, P., Paris, I. B., Díaz‐Véliz, G., Mora, S., Inzunza, J., Hultenby, K. R., Cárdenas, C., Jaña, F., Raisman‐Vozari, R., et al. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2182-5 · Cited by 44
Schneider, J. S. (1992) · Journal of Neuroscience Research · doi:10.1002/jnr.490310116 · Cited by 41
Ferrari, E., Engelen, M., Monzani, E., Sturini, M., Girotto, S., Bubacco, L., Zecca, L., & Casella, L. (2012) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-012-0951-7 · Cited by 38
Self-citationHuang, B., Wu, S., Wang, Z., Ge, L., Rizak, J. D., Wu, J., Li, J., Xu, L., Lv, L., Yin, Y., et al. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.03.026 · Cited by 37
Recent studies of ovine neuronal ceroid lipofuscinoses from BARN, the Batten Animal Research Network
Palmer, D. N., Neverman, N. J., Chen, J. Z., Chang, C.-T., Houweling, P. J., Barry, L. A., Tammen, I., Hughes, S. M., & Mitchell, N. L. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.06.013 · Cited by 35
Salazar, M. M., Td, S., & Pn, P. (1978) · PubMed · Cited by 35
Neural Differentiation in the Third Dimension: Generating a Human Midbrain
Marton, R. M., & Pașca, S. P. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.07.017 · Cited by 35
Applications of affinity chromatography to the study of drug–melanin binding interactions
Aubry, A. (2002) · Journal of Chromatography B · doi:10.1016/s0378-4347(01)00486-8 · Cited by 31
Chemistry and Chemical Equilibrium Dynamics of BMAA and Its Carbamate Adducts
Diaz-Parga, P., Goto, J. J., & Krishnan, V. V. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9801-2 · Cited by 30
Scott, L. L., & Downing, T. G. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-9996-5 · Cited by 29
Studies on the melanin affinity of haloperidol.
Lydén, A., Larsson, B. S., & Lindquist, N. G. (1982) · PubMed · Cited by 27
Hofer, T. (2001) · Journal of the Chemical Society Perkin Transactions 2 · doi:10.1039/b006394k · Cited by 23
Self-citationSynthesis and Pharmacological Evaluation of 1,2,3,4-Tetrahydro-.BETA.-carboline Derivatives.
KAWASHIMA, Y., HORIGUCHI, A., TAGUCHI, M., TUYUKI, Y., Karasawa, Y., Araki, H., & HATAYAMA, K. (1995) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.43.783 · Cited by 23
Tago, T., Toyohara, J., Harada, R., Furumoto, S., Okamura, N., Kudo, Y., Takahashi‐Fujigasaki, J., Murayama, S., & Ishii, K. (2019) · Annals of Nuclear Medicine · doi:10.1007/s12149-019-01344-x · Cited by 22
The Role of Xenobiotics and Trace Metals in Parkinson’s Disease
Bjørklund, G., Dadar, M., Chirumbolo, S., & Aaseth, J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01832-1 · Cited by 21
Label‐Free Nanoimaging of Neuromelanin in the Brain by Soft X‐ray Spectromicroscopy
Brooks, J., Everett, J. L., Lermyte, F., Tjhin, V. T., Banerjee, S., O’Connor, P. B., Morris, C. M., Sadler, P. J., Telling, N. D., & Collingwood, J. F. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202000239 · Cited by 21
Age-Related Histological Changes in the Canine Substantia Nigra.
Uchida, K., KIHARA, N., Hashimoto, K., Nakayama, H., Yamaguchi, R., & TATEYAMA, S. (2003) · Journal of Veterinary Medical Science · doi:10.1292/jvms.65.179 · Cited by 20
Model neuromelanins as antioxidative agents during lipid peroxidation
Wilczok, T., Stȩpień, K. B., Dzierżęga‐Lęcznar, A., Zajdel, A., & Wilczok, A. (1999) · Neurotoxicity Research · doi:10.1007/bf03033277 · Cited by 20
Magnetic beads method for determination of binding of drugs to melanin
Marszałł, M. P., Buciński, A., Goryński, K., Proszowska, A., & Kaliszan, R. (2010) · Journal of Chromatography A · doi:10.1016/j.chroma.2010.11.015 · Cited by 20
Myhre, O., Eide, D. M., Kleiven, S., Utkilen, H., & Hofer, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-20327-y · Cited by 18
Self-citationLindquist, N. G. (1972) · PubMed · Cited by 15
Segura-Aguilar, Sulzer, D., Zucca, F. A., & Zecca, L. (2019) · PubMed · Cited by 15
Self-citationNeuromelanin in the substantia nigra of adult horses.
Cozzi, B., Pellegrini, M., & Droghi, A. (1988) · PubMed · Cited by 13
The influence of iron on selected properties of synthetic pheomelanin
Żądło, A. C., Mokrzynski, K. T., Ito, S., Wakamatsu, K., & Sarna, T. (2020) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-020-00918-1 · Cited by 13
MPTP-induced Parkinson-like disease in sheep: clinical and pathologic findings.
Beale, A. M., Higgins, R. B., Work, T. M., Bailey, C. S., Smith, M. O., Shinka, T., & Hammock, B. D. (1989) · PubMed · Cited by 12
Neuromelanin inhibits CXCL10 expression in human astroglial cells
Tousi, N. S., Buck, D. J., Zecca, L., & Davis, R. L. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.09.042 · Cited by 11
Self-citationAn XAS study of the sulfur environment in human neuromelanin and its synthetic analogs
Crippa, P. R., Eisner, M., Morante, S., Stellato, F., Vicentin, F. C., & Zecca, L. (2009) · European Biophysics Journal · doi:10.1007/s00249-009-0462-9 · Cited by 11
Self-citationSaturation Binding of Nicotine to Synthetic Neuromelanin Demonstrated by Fluorescence Spectroscopy
Haining, R. L., Jones, T. M., & Hernandez, A. (2016) · Neurochemical Research · doi:10.1007/s11064-016-2068-9 · Cited by 11
Merighi, A., & Peirone, S. (1985) · PubMed · Cited by 10
Hofer, T., Myhre, O., Peltola-Thies, J., & Hirmann, D. (2021) · Environment International · doi:10.1016/j.envint.2021.106592 · Cited by 10
Self-citationヒト黒質およびしゅうはんの神経メラニンにおける 35 S-クロルプロマジンのin vitroでの蓄積作用
Lindquist, N. G. (1972) · Cited by 9
Kawashima, H., Iida, Y., Kitamura, Y., Kiyono, Y., Magata, Y., & Saji, H. (2002) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.89.426 · Cited by 8
Kawashima, H., Iida, Y., Kitamura, Y., & Saji, H. (2004) · Neurotoxicity Research · doi:10.1007/bf03033449 · Cited by 8
Levi, A. C., DeMattei, M., Ravazzani, R., Corvetti, G., Golden, G. T., & Fariello, R. G. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90390-x · Cited by 8
Bianchi, M., & Merighi, A. (1986) · PubMed · Cited by 8
Fink, J., Pathak, H., Smith, J. M., Achat‐Mendes, C., & Haining, R. L. (2019) · Biomolecules · doi:10.3390/biom9050175 · Cited by 7
Marszałł, M. P., Proszowska, A., Buciński, A., & Kaliszan, R. (2013) · Current Pharmaceutical Analysis · doi:10.2174/1573412911309020002 · Cited by 6
Mammalian toxicokinetic database (MamTKDB) 1.0
European Chemicals Agency (2021) · Publications Office of the European Union · doi:10.2906/101099104097/2 · Cited by 3
Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1
Cited by
Kabir, M. T., Rahman, M. H., Shah, M., Jamiruddin, M. R., Basak, D., Al-Harrasi, A., Bhatia, S., Ashraf, G. M., Najda, A., El-kott, A. F., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112610 · Cited by 181
Cerebral Iron Deposition in Neurodegeneration
Dusek, P., Hofer, T., Alexander, J., Roos, P. M., & Aaseth, J. O. (2022) · Biomolecules · doi:10.3390/biom12050714 · Cited by 159
Self-citationWise, R. M., Wagener, A., Fietzek, U. M., Klopstock, T., Mosharov, E. V., Zucca, F. A., Sulzer, D., Zecca, L., & Burbulla, L. F. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105920 · Cited by 99
Self-citationSun, J., Lin, X., Lu, D.-H., Wang, M., Li, K., Li, S., Li, Z., Zhu, C., Zhang, Z.-M., Yan, C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165228 · Cited by 95
Zucca, F. A., Capucciati, A., Bellei, C., Sarna, M., Sarna, T., Monzani, E., Casella, L., & Zecca, L. (2023) · IUBMB Life · doi:10.1002/iub.2654 · Cited by 69
“In addition, due to its poor solubility, NM could remain for long time in the extracellular milieu of SN sustaining this chronic inflammatory process that can be exacerbated also by release of toxic compounds and redox active metals immobilized into NM structure.(57,58) Synthetic melanins have been used to induce and…”
BackgroundSelf-citation
Metadata
- Authors
- Capucciati, A., Zucca, F. A., Monzani, E., Zecca, L., Casella, L., & Hofer, T.
- Affiliations
- University of Pavia (IT)
- Institute of Biomedical Technologies (IT)
- Norwegian Institute of Public Health (NO)
- Corresponding author
- Hofer, Tim
- Venue
- Antioxidants
- Publisher
- MDPI AG
- Published
- 2021-05-21
- Volume
- 10
- Issue
- 6
- Pages
- 824
- ISSN
- 2076-3921 (ISSN-L)
- PMC
- PMC8224073
- OpenAlex
- W3165207429
- Cited by
- 36
- References
- 143
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 4 · 2023: 12 · 2022: 6 · 2021: 1
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Antioxidants (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
- Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca (2015T778JW)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › melanin and skin pigmentation
- Keywords
- neuromelanin, xenobiotics, neurodegeneration, catecholaminergic neurons, metal ion binding, neurotoxicity, Parkinson's disease, Alzheimer's disease, brain aging, toxicant identification
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.